Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 14, Issue 27, 2008, Pages 4342-4346

  Nagy, Ferenc ^a   Molnár, Tamás ^a   Szepes, Zoltán ^a   Farkas, Klaudia ^a   Nyári, Tibor ^a   Lonovics, János ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

6 mercaptopurine; Azathioprine; Efficacy; Inflammatory bowel disease; Side effects

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; IRON; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IRON BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOPENIA; LIVER FUNCTION TEST; MALE; PANCREATITIS; SIDE EFFECT; ULCERATIVE COLITIS; MIDDLE AGED; PATHOLOGY;

6-MERCAPTOPURINE; ADRENAL CORTEX HORMONES; ADULT; AGED; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; STEROIDS;

EID: 55949090947     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.4342     Document Type: Article

References (30)

1. Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 160-170
2. Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J Clin Gastroenterol 1987; 9: 654-658
3. Katz JA. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 2002; 18: 435-440
4. Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin Drug Investig 2004; 24: 479-486
5. Robinson M. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol 1997; 92: 12S-17S
6. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-227
7. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28: 297-321
8. Tremaine WJ. Refractory IBD: medical management. Neth J Med 1997; 50: S12-S14
9. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-1233
10. Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl 1998; 225: 92-99
11. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5: V1-V16
12. Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23: 523-532
13. Makins R, Ballinger A. Gastrointestinal side effects of drugs. Expert Opin Drug Saf 2003; 2: 421-429
14. Egan LJ, Derijks LJ, Hommes DW. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 21-28
15. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-1157
16. Winter JW, Gaffney D, Shapiro D, Spooner RJ, Marinaki AM, Sanderson JD, Mills PR. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 1069-1077
17. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004; 33: 209-234, viii
18. Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 1133-1145
19. Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3657-3667
20. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743
21. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14: 1561-1565
22. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45: 1810-1813
23. McGovern DP, Travis SP, Duley J, Shobowale-Bakre el M, Dalton HR. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology 2002; 122: 838-839
24. Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol 2005; 40: 52-55
25. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-939
26. Jorgensen LG, Fredholm L, Hyltoft Petersen P, Hey H, Munkholm P, Brandslund I. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med 2005; 43: 403-411
27. Scholmerich J. Which immunosuppressors do you use to treat Crohn's disease and ulcerative colitis? In which order of priority and how worried are you about toxicity? Inflamm Bowel Dis 1998; 4: 248-252; discussion 253-254
28. Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG. Severe pulmonary toxicity after azathioprine/ 6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41: 682-688
29. Hanauer SB, Thisted RA. Treatment of Crohn's disease: the "long" of it. Gastroenterology 2005; 128: 2164-2166
30. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699-1708